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ABSTRACT 
 
HIV associated TB is not easy to make diagnosis and is linked with extreme disease 
and death. The spread of MDR-TB, together with increasing harmful of HIV 
infection and inadequate availability of quick examination instrument have lead to 
cause disappointment of global TB control. The intention of the study was to 
evaluate Gene Xpert MTB/RIF technique and smear auramine LED FM technique 
for detection of pulmonary tuberculosis (PTB) in people living with HIV at Mnazi 
Mmoja Hospital Zanzibar. The study was experimental type of design that involved 
laboratory analysis of sputum specimens for determination of Mycobacterium 
tuberculosis as well as rifampicin resistance for HIV patients. The specimens were 
processed in Gene Xpert MTB/RIF and smear auramine LED FM. The sum of 246 
patients sputum specimens were analyzed for the existence of Mycobacterium 
tuberculosis by means of Gene Xpert MTB/RIF and LED FM techniques. The results 
showed that 169 (68.7%) spot samples (sample I) and 169 (68.7%) morning samples 
(sample II) were positive for Gene Xpert MTB/RIF technique. Then 112 (45.5%) 
spot samples (sample I) and 118 (48.0%) morning samples (sample II) were smear 
positive (LED FM). The sensitivity of LED FM in spot samples and morning 
samples were 66.3% and 69.8% respectively. Among 169 positive TB cases 2 
patients were found with rifampicin resistance. The outcome of this study indicated 
that the performance of Gene Xpert MTB/RIF machine is more accuracy than LED 
FM in diagnosis of PTB in HIV patients suspected with TB. Gene Xpert MTB/RIF 
may be significant as a single quick method for PTB case finding in HIV patients 
suspected with active TB.    
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Background 
Tuberculosis is still a main public health problem in the world. WHO estimate that 
between 2000 – 2020, about one billion people will be newly infected, 200 million 
will become sick, as well as 35 million people will die from TB. Currently, HIV 
infection is known as the greatest risk factor for development of latent TB infection 
to active TB. Co-infection HIV and TB particularly in combination with drug 
resistance have caused outbreaks of increasing death rate. Mycobacterium 
tuberculosis is passed in airborne particles (droplet nuclei) generated when patients 
with pulmonary tuberculosis cough. These particles, 1 – 5 µm in size, are kept 
suspended by normal air current. Infection occurs when a susceptible person inhales 
the droplet nuclei. Once in the alveoli, the organisms are engulfed by alveolar 
macrophages. Normally, the cell mediated immunity of a host act to resist the 
multiplication and spread of MTB. However, some MTB can still be viable but 
inactive for several years after the early infection. The clinical features of PTB are 
cough, weight loss, night sweats, low grade fever, dyspnoea and chest pain (Murray, 
2003). 
 
Global prevalence of TB in 2013 was 159 per 100,000 populations (WHO, 2014). In 
the year 2013 nine million people who were infected with TB in the world, more 
than half (56%) were in the South-East Asia and Western Pacific Regions. One 
quarter was from Africa Region, which also had the maximum morbidity and 
mortality rates in relation to population. India and China, both accounted for 24% 
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and 11% of total cases respectively (WHO, 2014). Therefore, in 2013 Africa region 
scores the highest proportional of new infection of TB per population, which is 280 
per 100,000 populations (WHO, 2014). The prevalence of TB in United Republic of 
Tanzania is 295 per 100,000 populations. This shows that TB is still a major burden 
in the country, and in Zanzibar TB prevalence is 124 per 100,000 population 
(MOHSW, 2013). 
 
Today the TB epidemic facilitated by the most important factor in resource limited 
setting is bad economic condition, which is direct linked to poverty, malnutrition, 
poor settlement, lack of availability good health care services in free cost as well as 
community to go to tradition healers to search treatment which may facilitate spread 
of TB to the community (Cegielsk, 2004). In addition TB epidemic will continue to 
happen, particularly in Sub-Saharan Africa, due to co-infection of TB and HIV 
(Karp, 2007).  
 
So far, in third world countries a laboratory which performs TB culture is challenged 
by inadequate infrastructure, obsolete instrument and the issue of biosafety and 
biosecurity measures. Also lack of competent staff and financial issues add-up to the 
problem in these countries. Unfortunately, there is few reference laboratories which 
have ability to perform correctly TB culture and drug susceptibility test (Parsons, 
2011). Smear ZN stain and smear auramine stain for sputum by using light 
microscopy and LED FM are the standard methods to identify AFB in Zanzibar. If 
bacilli are present, the patient has sputum smear positive for PTB. When the MTB 
cannot be identified, chest X- ray is taken to assist with diagnosis (ZIHTLP, 2013). 
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The foundation of TB examination and case finding in large numbers of TB control 
programs is smear microscopy (Lawn, 2011). It is cheap and does not need 
sophisticated equipment and easy to perform because there are a few technical needs. 
In regions where burden of TB infection is high smear microscopy is suitable since it 
has the capacity of generating high positivity rate despite the difference range of its 
sensitivity of 35 to 80% (Mathew, 2002). 
 
The reagent of carbol fuchsin used in Ziehl Neelsen (ZN) stain technique is not 
suitable for the environmental as well as human in health. Whereas basic fuchsin, 
phenol and alcohol contain toxin, that cause damage to human through breathing, 
assimilation, drinking or eating. Accumulation of methanol poison less than 30 
milliliters in human has been reported to cause fatality when eating or drinking. This 
poison causes abnormality of CNS such as depression, convulsion, also causes 
headache, nausea, dizziness, pupils dilatation and intoxication. The outcome of this 
problem may be coma or mortality. In addition to that, loss of vision may happen due 
to methanol poison. Phenol is very toxic; when it comes into contact with human 
skin it causes chemical burns. In the environment alcohol reagent is decompose 
naturally, but basic fuchsin and phenol are not biodegradable, hence dangerous to 
plant and wildlife (MCC, 2014). 
 
Gene Xpert MTB/RIF is friendly to the environment.  Xpert MTB/RIF assay present 
very low risk to testing personnel. The Xpert MTB/RIF assay starts with addition of 
highly tuberculocidal sample treatment reagent (SR) to each sputum sample; it 
reduces the viability of MTB in sputum after 15 minutes of incubation. After 
incubation the sputum SR mixture is transferred to the plastic assay cartridge, the 
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cartridge lid is closed and pressed in Xpert instrument. The remainder of the assay is 
performed within the closed cartridge. The use of closed cartridge system further 
reduces biohazard risk by performing sample processing in an aerosol resistant 
enclosure (Banada, 2010).  
  
Health care sites which located in peripheral for the time being have a challenge 
concerning availability of a quick method for diagnosis of active TB infection. 
Therefore, patients with co-infection TB and HIV or active TB cases in endemic 
areas miss laboratory diagnosis and are treated clinically with improper drugs. Hence 
forth, facilitate TB infection to spread in society (Horries, 2010). 
 
Success of accurate diagnosis of TB infection in people living with HIV is not very 
easy compared to immunocompetent people (Sterling, 2010). An HIV patient 
infected with TB infection tends to have very small number of TB organisms, that‟s 
why the accuracy of sputum smear microscopy is limited (Sterling, 2010; Getahun, 
2010). Besides patients suffering with advanced immunocompromise are highly 
susceptible to infection with TB. Rapid and accurate diagnosis of TB is very 
important in HIV patients in order to initiate early treatment and thus decrease death 
related to TB (Carriquiry, 2012).  
 
The verification of TB and MDR-TB in the laboratory is useful in ensuring that 
people who develop sign and symptoms are properly examined and immediately  
provided with effective treatment. In 2013, out of 4.6 million cases (new and relapse) 
PTB reported in the world, 2.8 million were identified positive to MTB by all 
methods recommended by WHO (WHO, 2014). Identification of TB without 
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performing DST examination is not proper as it can cause unsuccessful treatment and 
facilitate to disseminate drug resistance strain in the community and more money 
used to cure patients (WHO, 2014). 
 
In places with inadequate resources for TB diagnosis and where the prevalence of 
HIV is high, urgent measures are required to implement new and rapid detection of 
TB. Whereas, laboratory examination of MTB from Culture is the gold standard. 
However, culture of MTB takes a number of days to provide results and is costly in 
terms of laboratory facilities, hence not a recommended method for management of 
severe cases. Recently, WHO authorized the implementation of Gene Xpert 
MTB/RIF and LED FM for national TB control programmes in third world countries 
(WHO, 2011). 
 
The Xpert MTB/RIF is a new fully automated diagnostic molecular test with an 
analytic sensitivity of five genome copies of purified DNA and 131 cfu/ml of M. 
tuberculosis in sputum, moreover, it is able to detect more than 99.5% rifampicin 
resistance mutations, an indicator of MDR-TB, in less than two hours. The Gene 
Xpert machine does not requires sophisticated laboratory facilities. It needs 
minimum biosafety and training and data from many clinical validation studies 
indicate 92% sensitivity compared to culture utilizing a single specimen (WHO, 
2011).  
 
However, these data come from clinical trials, and information about the 
performance of LED fluorescent microscopy and Xpert MTB/RIF in real-life 
situations is desirable before worldwide implementation. The aim of this study was 
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assess the two techniques (i.e., Gene Xpert and LED FM technique) for detection of 
PTB in HIV patients.  
 
1.2 Statement of Research Problem 
Environmental factors which facilitate the possibility of the threat for MTB 
dissemination to increase are contact to TB in small closed area, insufficient 
ventilation which provides infectious TB droplets, unable to follow safety procedure 
effectively during samples handling, improper decontamination of medical 
instruments and recirculation of infectious TB droplets in the air (CDC, 2005). 
   
Repeated visit for collection of spot and morning sputum samples causes the problem 
of patients dropout in health care facilities. More patients faced a challenge to get 
fare transport for submission of samples to heath care facilities and compilation of 
result. In fact the sensitivity of smear microscopy depend on the quality of samples 
which has been collected, quality of stain reagents and slide smear prepared, that is 
why there are variation range of 20% to 85% concerning sensitivity (Steingart, 
2007). In addition, sputum smear microscopy loss its sensitivity for diagnosis of HIV 
patients infected with TB and for children due to small number of MTB in the 
patients (Fox, 1999).  
 
The HIV infection leads to decreased number of cell mediated immunity, this 
situation not only lead to boost the TB disease but also change the way of clinical 
diagnosis of TB infection. When HIV infection continues to develop the number of 
CD4 T- lymphocytes decrease and facilitate to stimulate the growth and replication 
of MTB. CD4 T- lymphocytes play the role for immune response against infection. 
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HIV associated TB is not easy to diagnize and is linked to extreme disease and death. 
The spread of MDR-TB, together with increasing harmful of HIV infection and 
inadequate availability of quick diagnostic instrument have lead to disappointment of 
global TB control. Furthermore, due to changing of clinical diagnosis of TB and 
interruption of treatment of TB infection, contribute to increased dissemination of 
TB within societies.  
 
In general to attain successful control of TB it is important to collaborate with 
stakeholders for case finding to the community particularly to HIV patients and 
provide immediate effective treatments to those TB patients. The present study 
assessed two techniques GeneXpert assay and LED auramine fluorescent microscopy 
for diagnosis of PTB in HIV victims at MMH Zanzibar. 
 
1.3 Objectives 
1.3.1 General Objective 
To compare Gene Xpert MTB/RIF technique and LED fluorescent microscopy 
technique for diagnosis of pulmonary TB in HIV victim. 
 
1.3.2 Specific Objective 
(i) To evaluate the accuracy of Gene Xpert machine and LED FM for diagnosis of 
PTB. 
(ii) To determine the sensitivity and specificity of smear auramine FM for PTB 
diagnosis in the study area. 
(iii) To investigate the occurrence of MDR-TB in the study area. 
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1.4 Hypotheses 
(i) Gene Xpert MTB/RIF is more accuracy than LED FM in diagnosis of PTB. 
(ii) Smear auramine FM is less sensitivity but has high specificity for PTB 
diagnosis. 
(iii) The prevalence of MDR TB is less in the study area. 
 
1.5 Significance of the Study 
The issue of safe environment in diagnosis of MTB in laboratory is very vital. The 
use of engineering controls (For example BSC and area exposure to air) and personal 
protective equipment (like oxygen mask) can help to protect laboratory personnel 
against exposure with TB infection in linked with breathing of infectious droplets. 
On the other hand, the major significant concept in the testing area is to diminish the 
threat of generating aerosols within and outside the work environment so that to 
decrease the danger of exposure with infectious agents. 
 
There is a lack of accurate and rapid diagnosis technique for TB in many health 
centers in Zanzibar. Definitely this study will provide useful and valuable 
information to policy makers about accurate and rapid diagnosis technique for TB. 
Determination of accurate and rapid diagnosis technique for TB could help to reduce 
death by providing proper treatment to those patients suffering with HIV and TB co-
infection as well as to keep environment well against contamination with aerosol 
when processing sputum. Then the importance of this study was to find rapid and 
accurate technique for diagnosis of PTB in patients suffering with HIV and TB co-
infection. 
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CHAPTER TWO 
LITERATURE REVIEW 
 
2.1 Common Knowledge Concerning Tuberculosis 
Tuberculosis is a persistence infectious illness caused mostly by Mycobacterium 
tuberculosis (and rarely by Mycobacterium bovis or Mycobacterium africanum). 
Another name of these organism is known as acid fast bacilli (AFB) because they are 
decolorized by acid alcohol. The lungs are affected when organisms penetrate the 
body through breathing. Normally there are two kinds of tuberculosis: first PTB 
which damage the respiratory organs, this type of disease is common to the 
community. The second is extra pulmonary tuberculosis (EPT) is the infection that 
damage other organ than the respiratory organ such as joint, lymph nodes, spine, 
brain, pleural and genital urinary tract (TURT-MOH, 2006). 
 
2.1.1 Spread of Tuberculosis 
TB is a communicable disease; the route of infection is person to person contact 
through inhalation. The individual who is affected by PTB can transmit the 
infectious droplets when coughing, talking or sneezing into the recirculated air. The 
exposure of this facilitated by environmental factors such as small closed area and 
insufficient ventilation provide infectious TB droplets. These infectious droplets can 
be eradicated in the building by providing well ventilation. TB organisms die within 
minutes when exposed to direct sunlight; however they are alive in a dark area for 24 
to 48 hrs. Health individual staying together with a patient confirmed PTB positive in 
a small room that lack good ventilation for a long time is susceptible to TB infection. 
The danger of dissemination of TB from individual with negative smear PTB is low. 
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Smoking and silicosis boost the vulnerability to disease. However, facilities which 
have nice ventilation dissolve the mass of infectious agents (TURT-MOH, 2006). 
 
            The threat of development infection to active TB disease depends on the condition of 
the immune system. Normal people with HIV negative are able to resist TB disease 
to about 90% even though they acquire infectious agent of TB due to the active 
immune response. Only tuberculin skin test may be indicating positivity of TB 
infection to immunocompetent individual. The condition of immunocompromise 
stimulates the dormant bacilli to be active and cause TB disease to an individual 
because the cells associated with immune response become weak and fail to fight 
against infectious agents (TURT-MOH, 2006). 
 
Currently, HIV infection is the source which cause immune suppression and lead to 
reactivation of TB in Tanzania. Co-infection TB and HIV individuals have 29 – 30 
times chance of progression to active TB disease than HIV negative individuals. 
Also there are other conditions such as recurrent infection of any kind, malnutrition 
and diabetes mellitus may cause reactivation of the TB infection (TURT-MOH, 
2006). 
 
2.2 Prevalence of Mycobacterium tuberculosis 
In 2013, about 1.1 million (13%) of the 9.0 million people who were infected with 
TB disease globally were HIV positive. The African region accounted for 78% of the 
estimated number of HIV positive incident TB cases. Since 2004 the mortality rate of 
people with co-infection HIV and TB has been decreasing. Nevertheless, in 2013 the 
mortality of HIV related with TB was still 360,000 in the world (WHO, 2014). 
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Although majority of the TB morbidity and mortality arise among men, also the 
number of TB cases among women is high. About 3.3 million cases of TB and 
51,000 TB mortality among women, and about 550,000 TB cases and mortality 
80,000 among children happened in the year 2013. The high number of deaths would 
be preventable, if the individuals may arrive at health facilities for diagnosis and 
appropriate treatment, this would decrease the TB mortality rate.  
 
In fact the first line drugs for TB available at health facilities for decades may heal 
TB disease about 90% (WHO, 2014). Zanzibar is estimated to have 7,200 people 
living with HIV, this account for the prevalence of HIV to about 0.6%. HIV infected 
clients attending care and treatment services are screened for TB at each encounter. 
These include patient on ART, Isoniazid Preventive Therapy (IPT) or stopped IPT, 
adult and children, male and female, with exception of those on TB therapy.  
 
Percentage of patients screened for TB has increased from 97.1% in 2011 and 2012 
to 99% in 2013. Table 2.1 shows the number of HIV patient who were screened for 
TB out of those who received care during the period and those started on TB 
treatment (ZIHTLP, 2013). Currently there are two sites providing comprehensive 
TB/HIV activities (Mnazi Mmoja and Chake Chake Hospitals). 
 
TB patients who are diagnosed as HIV positive are treated at TB clinic and receive 
ARV drugs until they finish TB treatment when they are referred to care and 
treatment counseling. A total of 71 patients received ART at TB/HIV under one roof 
clinic in 2013 (ZIHTLP, 2013). 
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Table 2.1: Number of HIV Patients Screened for TB by Facility, 2013 
Care and Treatment 
Counseling 
Total 
Visit 
Screened for TB Started on TB Treatment 
  < 14 Years >14 Years < 14 Years >14 Years 
Al Rahma 140 6 134 0 1 
Bububu 377 18 359 1 8 
Kivunge 224 19 205 2 4 
Mnazi Mmoja 2521 216 2305 18 62 
Mwembeladu 606 41 565 1 3 
Chake Chake 217 23 194 1 5 
Mkoani 35 2 33 0 1 
Wete 157 25 132 1 10 
Micheweni 63 13 50 0 2 
Makunduchi 56 4 52 0 0 
Total 4,396 367 4,029 24 96 
Source: ZIHTLP (2013) 
 
Among all TB patient screened in 2013 a total of 115 (17.5%) patients tested were 
HIV positive. This is an increase compared to 79 (16.8%) patients who were 
diagnosed to be TB/HIV co-infected in 2012. The number of smear positive TB 
cases has also increased by 5% compared to 2012. This shows that, TB infection in 
the community is still high. As in the previous year, most of those affected are young 
adults in the age group between 15 – 44 years. It shows that 77 (24, 21%) were 
female and 141 (44.33%) were male, as shown in the Table 2.3 (ZIHTLP, 2013). 
 
Table 2.2: The Trend of Notification of TB for 10 Years 
Year 
 
Pulmonary 
tuberculosis 
AFB + 
Extra pulmonary 
tuberculosis 
AFB + 
Relapse Failure/
Others 
Returns Total 
2004 222 56 11 6 1 296 
2005 211 53 14 5 5 288 
2006 238 44 9 7 5 303 
2007 232 48 11 3 5 299 
2008 265 73 14 4 3 359 
2009 235 76 25 9 3 350 
2010 270 66 14 11 3 369 
2011 280 73 12 14 9 388 
2012 303 81 12 8 7 411 
2013 318 197 18 2 5 542 
Source: ZIHTLP (2013) 
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Table 2.3: Distribution of New Sputum Smear Positive (SSP) Cases by Age and 
Sex for the Year 2013 
 Age groups 0 – 4 5 – 14 15–24 25–34 35–44 45–54 55–64 65 + Total 
Male (SSP) 0 6 41 58 42 34 14 14 209 
Female (SSP) 0 5 27 30 20 15 5 7 109 
Total 0 11 68 88 62 49 19 21 318 
Source: ZIHTLP (2013) 
 
2.3 Prevalence of MDR TB 
Multidrug resistant tuberculosis (MDR-TB) is defined as tuberculosis resistant to at 
least isoniazid and rifampicin, the most powerful anti-TB drugs. Globally, an 
estimated 3.5% of new cases and 20.5% of previous treated cases have MDR-TB. In 
2013, there were an estimated 480,000 new cases of MDR-TB worldwide, and 
approximately 210,000 deaths from MDR-TB. Among patients with PTB who were 
notified in 2013, an estimated 300,000 had MDR-TB. More than half of these 
patients were in India, China and Russian federation (WHO, 2014). 
 
Between 2009 and the end of June 2014, nearly 90,000 people with MDR-TB were 
detected through the expand TB project, which has established capacity to detect 
drug resistant TB using line probe assay, liquid culture and Xpert MTB/RIF in 27 
low and middle income countries (WHO, 2014).  
 
In Zanzibar epidemiological data for MDR-TB prevalence is low, the reasons for low 
prevalence of MRD-TB may be lack of accurate diagnosis for detecting MDR-TB 
from patients. Also community is not aware about MDR-TB. The equipment, which 
detects the indicator for MDR-TB, is available only at MMH, which was 
commissioned in 2013. The trend of MDR TB as shown in Table 2.4 (ZIHTLP, 
2014). 
 
 
14 
Table 2.4: Trend of MDR TB in Zanzibar for the Past Six Years 
Serial number Year Unguja Pemba 
1. 2009 0 1 
2. 2010 2 0 
3. 2011 0 1 
4. 2012 0 0 
5. 2013 0 1 
6. 2014 2 0 
Source: ZIHTLP (2014) 
 
2.4 Current Status of TB Diagnosis 
In Zanzibar a total of diagnostic centers are 51. Unguja have 32 and Pemba 19 
centers. The health centers in unguja which has LED FM are 7 and 25 centers has 
ordinary light microscopy for the diagnosis of MTB. Also in Pemba 8 centers has 
LED FM and 11 has ordinary light microscopy. Only one centre (i.e Mnazi Mmoja 
Hospital) has Gene Xpert MTB/RIF (ZIHTLP, 2014). 
 
Table 2.5: Zanzibar Health Centers which have LED FM  
UNGUJA PEMBA 
Mnazi Mmoja Hospital Public health laboratory 
Kivunge Cottage Hospital Bogoa PHCU 
Makunduchi Cottage Hospital Vitongoji Cottage Hospital 
Rahaleo PHCU Abdulla Mzee Hospital 
Kiomba mvua PHCU Konde PHCU 
Fuoni PHCU Chakechake Hospital 
Jambiani PHCU Wete Hospital 
 Micheweni Cottage Hospital 
Source: ZIHTLP (2014) 
 
2.5 Delays in Diagnosis of TB 
Diagnosis of tuberculosis (TB) is often delayed in resource-limited settings. Factors 
contributing to the delayed diagnosis of TB include: 1) patient delays, 2) health-
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system delays and, 3) delays inherent to the conventional TB diagnostic process 
(Storla, 2008 and Sreeramareddy, 2009). Of these, delays related to the low 
sensitivity of sputum AFB smear microscopy, have been identified as the most 
significant contributor to the total diagnostic delay times experienced by TB patients 
(Millen, .2008). The consequences of delayed TB diagnosis and treatment include 
increased TB-related morbidity, increased mortality, and continued TB transmission 
(Greenaway, 2002; a Golub, 2006). In countries with a high burden of HIV, HIV 
infection has both reduced the sensitivity of smear microscopy contributing to further 
delays in TB diagnosis, while simultaneously increasing the urgency in which a rapid 
TB diagnosis is needed. 
 
Two multi-centre studies: the first study using rapid molecular detection of TB and 
rifampicin resistance and the second study using feasibility, diagnostic accuracy and 
effectiveness of decentralized of Xpert MTB/RIF test for diagnosis of TB and MDR 
have provided strong evidence that Xpert MTB/RIF (Cepheid, Sunnyvale, CA, 
USA), the first commercially available, automated, real-time NAAT for MTB, could 
reduce diagnostic delay (Boehme, 2010 and Boehme, 2011). Xpert MTB/RIF was 
found to be highly accurate (including 70% sensitivity in AFB smear-negative 
patients) and led to more rapid diagnosis and shorter time-to-TB treatment initiation 
compared to sputum smear microscopy (Boehme, 2010 and Boehme, 2011). Xpert 
MTB/RIF was also simple to perform and required minimal technician training. 
However, the clinical impact of more rapid TB diagnosis via Xpert MTB/RIF has not 
been adequately evaluated. Reducing diagnostic delays may be of particular 
importance in populations at high risk of early mortality. 
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2.6 Xpert MTB/RIF Diagnosis 
In the study performed in South Africa with HIV-infected patients, the Xpert 
MTB/RIF increased case detection for TB by 45% compared to FM (Lawn, 2011). 
WHO recommended the use of Xpert MTB/RIF for diagnosis of HIV associated PTB 
(Golub, 2006). However, the cost of Xpert MTB/RIF can be too high for some 
resource limited settings. In the study which was conducted in a District Hospital in 
India concerning the Xpert MTB/RIF compared with LED FM the following results 
were obtained as shown in Table 2.6 (Alvares-Uria, 2012). 
 
Table 2.6: Positive Results Utilizing LED FM and Xpert MTB/RIF Assay  
Sample Tota
l 
Smear positive X-pert positive Absolute 
difference 
Ratio                 
X-pert/LED 
# # % (95% CI) # %  (95% CI) % (95% 
CI) 
 (95% CI) 
Sputum 166 106 63.9 (56.2 to 
70.6) 
124 74.7 (67.5 to 
80.8) 
10.8 (5.2 to 
16.5) 
1.17 (1.08 to 
1.26) 
Source:  Alvares-Uria (2012) 
 
In setting with low prevalence of MDR TB where it is possible to obtain two 
additional early morning sputum samples in different days, LED FM could be used 
with not much loss of sensitivity compared to the Xpert MTB/RIF assay for 
diagnosis of HIV infected patients with suspicion of PTB (Alvares-Uria, 2012).  
 
WHO approved the Xpert MTB/RIF assay for sputum based rapid diagnosis of PTB 
and MDR TB. The assay can be used to accurately measure the MTB load beyond 
the detection limit of 131 organisms per mL in an in-vitro suspension (Helb, 2010). 
The Xpert MTB/RIF assay in patients with suspected TB and newly diagnosis case 
TB has been evaluated in several studies (Theron, 2011). 
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2.7 Smear Auramine FM Diagnosis 
Researchers are also looking at improving the accuracy of smear microscopy, which 
remain the first line diagnostic test for MTB for much of the world for foreseeable 
future. LED FM is more sensitive than standard microscopy (Smart, 2012). Since 
2012, LED FM has been introduced in about 200 medical college microscopy centers 
in India. Given better sensitivity (10% more) of LED FM over ZN microscopy, it 
may be possible that LED FM in spot specimens performed better in detecting AFB 
and the difference in performance between spot and early morning specimen may be 
lower (Cuevas, 2011). 
 
After systematic review and meta analysis of available data, WHO reported that in 
comparison with direct ZN (standard) microscopy. LED FM was statistically 
significantly more sensitive by 6% (95% CI, 0.1 – 13%), with no appreciable loss in 
specificity, and LED FM was 5% (95% CI, 0 – 11%) more sensitive and 1% (95% 
CI, 0.7 – 3%) more specific than Conventional FM (WHO, 2011). 
 
2.8 Importance of Accurate and Rapid Diagnosis of TB and Drug Resistant 
Modelling studies have estimate that 400,000 lives could be saved each year with the 
introduction of an accurate, rapid and widely available TB diagnostic system with 
sensitivity greater than 85% for both smear positive and smear negative cases and 
97% specificity (Malicotti, 2014). 
 
The ability to rapid and accurately detect drug resistance in MTB clinical specimens 
is essential for appropriate treatment to be initiated in patients suffering from TB and 
for prevention of further spread of drug resistant strains. This is of paramount 
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importance for TB control of MDR-TB at national and global level (Drobniewsk, 
2013). 
 
2.9 Environmental Control in TB Diagnosis 
In the diagnosis of MTB in laboratory environmental controls is very important so 
that to avoid the transmission and decrease the concentration of infectious aerosol in 
ambient air. Environmental controls include the following technologies to removal or 
inactivate MTB: Local exhaust ventilation, general ventilation, high efficient 
particulate air (HEPA) filtration, and ultraviolet germicidal irradiation (UVGI).  
 
These controls help to stop the transmission and decrease the concentration of 
airborne infectious agents. Environmental controls are the second line of defense in 
the TB infection control program, and they work in harmony with administrative 
controls. The reduction of exposure can be facilitated through the effective use of 
environmental controls at the source of exposure (e.g., coughing patient or laboratory 
specimen) or in the general work place environment. General ventilation can be used 
to dilute the air and remove air contaminants and to control air flow patterns in room 
or in health care setting. Air cleaning technologies include HEPA filtration to reduce 
the concentration of MTB droplet nuclei and UVGI to kill or inactivate the 
microorganism so that they no longer pose a risk of infection (CDC, 2005). 
 
Class II BSCs in Figure 2.1 provide personnel protection (containment), product 
protection (a virtually particle free work area to help minimize contamination of 
culture or other products), and environmental protection (helps prevent 
contamination of laboratory, the building and the community). Characteristics that 
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are shared by all types of class II BSCs have two HEPA filters, a supply filter and an 
exhaust filter. All of the air leaving the work area is HEPA filtered by either the 
supply filter or the exhaust filter. The exhaust filter provides environmental 
protection by preventing particulates from escaping via the exhaust air duct 
(Fleming, 2006).  
 
Xpert MTB/RIF assay posses a smaller biohazard risk than the performance of a 
direct AFB smear. Any type of sputum manipulation, including AFB smear 
preparation, can generate potentially infectious aerosols from a sputum sample 
containing a sufficient number of bacteria. The combination of an effective 
tuberculocidal SR and the closed configuration of the Xpert MTB/RIF cartridge 
effectively reduce the risk of infectious aerosol formation to below that of AFB 
smear preparation. These features help to make the Xpert MTB/RIF assay suitable 
for near patient detection of TB and drug resistance in settings where biocontaiment 
facilities are not available (Banada, 2010). 
 
 
Figure 2.1: Sputum Samples Processed in Class II Biological Safety Cabinet 
Source:  Pathology Laboratory Mnazi Mmoja Hospital Zanzibar, (2015) 
 
 
20 
CHAPTER THREE 
MATERIALS AND METHODS  
 
3.1 Study Design 
The study was experimental type of design that involved laboratory analysis of 
sputum samples for determination of AFB and rifampicin resistance for the HIV 
patients attending CTC at Mnazi Mmoja Hospital from all districts of Unguja Island. 
 
3.2 Study Area 
The study was done at Mnazi Mmoja Referral Hospital in Zanzibar specifically at 
CTC where the samples were collected and then laboratory test conducted at TB 
section in microbiology department. The study was conducted from 5
th
 April to 10
th
 
August 2015. Therefore, this study in Zanzibar provides a base line data to other 
studies. 
 
Mnazi Mmoja is the main referral hospital in Zanzibar. The hospital itself is located 
at Urban west region in the Stone Town, the historic centre of Zanzibar City. It 
comprises of outpatient clinic, specialized clinics and several wards for the inpatient 
services. Although termed as referral hospital, basic outpatient services are also 
provided to the nearby communities. 
 
The hospital contains 450 beds. The specialty departments include paediatrics, 
surgery, internal medicine, acupuncture, physiotherapy, occupational 
therapy, obstetrics and gynaecology, maternity services, dental and eye 
(ophthalomology). The hospital is fairly well-staffed with doctors, nurses, mid-
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wives, nursing students and a number of foreign medical students. Regularly foreign 
doctors also work at the hospital, which is the product of medical exchange 
programmes between Zanzibar and other countries such as Cuba, China, Egypt, 
Russia and Sweden. 
 
This hospital has a good laboratory with well-equipped equipment. This equipment 
includes; CD4 count machines, automatic tissue processor, ELISA reader, teach 
microscopes and genexpert machine. The laboratory has six departments which are 
microbiology, parasitology, clinical chemistry, haematology, histopathology and 
blood transfusion. The laboratory is three stars ranked and has about 55 staffs. 
Among these; they have one pathologist, four laboratory scientists, twenty one 
technologists, twenty three technicians and six laboratory assistants. 
 
 
Figure 3.1: Map of Zanzibar Stone Town showing Location of Mnazi Mmoja 
Hospital where Sputum was Collected 
Source: https:/www.google.oc.tz/maps/placemnazimmojaHospital 
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Zanzibar consists of two sisters Islands named Unguja (Zanzibar) and Pemba, the 
land area of the two Islands is approximately 2,332 square kilometers. Zanzibar is 
1,464 square kilometers. The population of Zanzibar is approximately 1.303,569 
based on 2012 National census. 
 
It is located about 35km off the cost of Dar es Salaam (commercial capital city of 
Tanzania), between 39 degree longitudinal and 6 degree latitude south of equator. 
Zanzibar Island has 5 regions; Unguja Island has 3 regions named Urban west, North 
and South. Pemba Island has 2 regions named North and south. 
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Figure 3.2:   Map of Unguja Island showing TB Diagnosis Centres 
Source: www.faysafaris.com/Tanzania Maps.htm 
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3.3 Study Population 
Study population included all HIV patients male and female suspected with TB 
attending CTC and TB clinic at Mnazi Mmoja Hospital. All agreed and signed the 
informed consent form for the study purpose. 
 
(a) Inclusion criteria of patient 
(i) All HIV patients suspects with TB overt 18 years  
(ii) Must have capability of producing two quality sputum samples 
(iii) Cough duration must be two weeks or more 
 
(b) Exclusion criteria patient 
(i) HIV patient(s) less than 18 years old were not allowed to participate in the 
study. 
(ii) HIV patient(s) who were not able to produce quality sputum was not 
involved. 
(iii) HIV patient(s) with less than two weeks of coughing episodes were 
excluded. 
 
3.4 Sample Size 
The formula for calculating sample size was available in (htpp://www.caribvet. 13
th
 
February, 2015). The prevalence was determined by regarding the number of PTB 
cases during a specified time period in the study area. The size of the population of 
PTB patients occurred in study area. The prevalence was then calculated by dividing 
the number of PTB incidence during specified time period by the size of population 
of HIV patients, the result is expressed as a percentage. The total numbers of PTB 
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cases reported in Zanzibar between 2009 – 2013 were 1506 and the total numbers of 
the population were 7200. The prevalence was calculated as shown 1506/7200 = 0.2 
(20%). Therefore the prevalence of PTB was 0.2. In this study 246 HIV patients 
male and female attended CTC at MMH were examined. Those HIV patients 
suspected with PTB were used in the study to represent the population. The numbers 
of sputum samples collected are shown below. 
n=   Z²1-α/2 P(1-P)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                e² 
Where n= number to sample 
             Z²= (1.96)² for 95% confidence (i.e. α= 0.05) 
             P= 0.2 
             e= maximum tolerable error for the prevalence estimation 0.05 
From formula above n = (1.96)² x 0.2(1 – 0.2) 
                                                   (0.05)² 
                                  n = 246 
 
3.5 Specimen Collection 
Two sputum samples were requested from all HIV patients suspects with TB 
according to inclusion and exclusion criteria mentioned above. One on-the-spot 
sputum sample at the time of the patient's first visit, and an early morning sputum 
sample taken by the patient at home on the day following the initial visit.  Patients 
were instructed on production of good quality sputum samples. Biological safety 
cabinet was used when specimens were assessed macroscopically to inspect the 
quality and quantity and a record was made.  
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3.6 Sample Transport      
 All sputum samples were transported to the laboratory in clean containers, and 
transported in cooler box after collection. Sample were labeled by necessary 
information including name and number of patient, number of sample either 1 or 2, 
date of collection.  
 
3.7 Materials and Equipments                              
3.7.1 For Gene Xpert Technique 
 
 
Figure 3.3:   Gene Xpert MTB/RIF Machine 
Reagents Supplies Equipment 
 GeneXpert Kit including: 
Xpert cartridges, sterile 
disposable transfer pipettes, 
Sample Reagent (SR) buffer 
(Pro-Gen Diagnostics) 
 Tap Water 
 70% Ethanol 
 3.5% or 5% Sodium 
hypochlorite (Bleach) 
 Screw-capped sputum 
containers 
 Pasture pipette  
 Disposable Gloves 
 Laboratory coat 
 Soap 
 Permanent marking 
pens 
 Tidy wipe/paper towel 
 Biohazard medical waste 
bin 
 The GeneXpert Dx 
System includes 
GeneXpert instrument, 
computer and barcode 
scanner, UPS, printer 
(Pro-Gen Diagnostics) 
 Stop watch/timer 
 500ml measuring 
cylinder 
 Memory stick/RW-
CD‟s for data backup 
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Source: Pathology Laboratory Mnazi Mmoja Hospital (2014) 
3.7.1.1   Diagnosis of Sputum Samples by GeneXpert MTB/RIF Technique 
GeneXpert machine was easy to perform, gave results within 2 hours of sample 
processed and there was no operation difficult during its usage. This is automated 
method; both spot and morning sputum samples were processed in this machine to 
identify the presence of MTB in the sputum. Processed of sputum in GeneXpert 
MTB/RIF assay (see appendix 3)  
3.7.1.2   Comparison Between GeneXpert MTB/RIF and LED FM Techniques 
Comparisons of these two techniques were done after sputum samples examined. 
The results of sputum samples generated from GeneXpert were compared with the 
results yielded by LED FM technique 
3.7.1.3   Investigate of MDR-TB in the Study Area 
GeneXpert MTB/RIF machine is an automated machine which used to detect MTB 
and rifampicin resistance. The rifampicin resistance is an indicator of MDR-TB. All 
sputum samples collected were done in GeneXpert MTB/RIF machine, processed of 
sputum (see appendix 3), all results yielded were analyzed to identify if there were a 
results of rifampicin resistance. In fact machine itself generate this results. 
3.7.2  For Auramine Staining Technique 
Requirements for performing this technique were as follows: 
(i) Timer 
(ii) Fluorescent microscope 
(iii) Bunsen burner or alcohol lamp 
(iv) Slide rack to support slides over the sink 
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(v) Slide rack for drying stained slides 
(vi) Sink with water 
(vii) Forceps 
(viii) Diamond pencil 
(ix) Waste bin 
(x) Positive and negative control slides  
(xi) Paper filters 32.0 cm in size 
(xii) Gloves 
(xiii) Slides 
(xiv) 0.1% of auramine 
(xv) 0.5% of acid-alcohol 
(xvi) 0.5 of potassium permanganate or 0.3 of methylene blue 
 
 
 
 
29 
Figure 3.4:   Fluorescent Microscope 
Source:  Pathology Laboratory Mnazi Mmoja Hospital Zanzibar (2014)  
3.7.2.1   Diagnosis of Sputum Samples by LED FM Technique 
All spot and morning sputum samples were processed. An appropriate portion of the 
sputum samples (from the most purulent portion) was collected with an applicator 
stick or a wire loop and spread on the labelled side of the microscope slide. The 
slides were air dried and then heat-fixed.  All smears were stained by the FM 
technique (See appendix 2). 
 
3.8 Examination 
All slides were examined blindly by FM at 20 - 25 X objectives to scan the smear 
and 40X objectives for confirming AFB.  The AFB was graded according to the 
following scheme:  
N of AFB Report 
No AFB/1 length Negative 
1-29 AFB/1 length Record exact number 
1 - 9 AFB/ fields on average 1+ 
10-100 AFB/field on average 2+ 
> 100 AFB/ field on average 3+ 
 
3.9 Permission and Ethical Consideration  
Ethical clearance was sought and obtained from the concerned authorities for sample 
collection which is the Ethical Committee of the Ministry of Health Zanzibar. During 
the study, the purpose, procedures of the study, measures taken to ensure 
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confidentiality of the participants, the voluntary nature of the study and applicability 
of findings were explained to participants. Participants were assured that their 
participation in the study is voluntary and they are free to withdraw without any 
negative impact in their treatment at the clinic. Written informed consent was sought 
and obtained from the participants, since the study dealt with human and involved 
collection of sample direct from human the consensus of participants was necessary. 
 
3.10 Quality Control 
Both positive and negative slides were used for internal quality control during 
samples processed. 
 
3.11 Data Analysis 
All data analysis was performed using SPSS version 20 software. Comparison of 
performance of Gene Xpert MTB/RIF and LED FM were performed. Sensitivity, 
specificity and Pearson chi-square were performed to compare two diagnostic 
techniques. A p value (< 0.05) was considered significant. 
 
Objective Analytical Tool 
 
To compare the diagnosis accuracy 
of Gene Xpert MTB/RIF and LED 
FM among TB suspect 
Pearson  chi-square test used to determine 
association between the Gene Xpert 
MTB/RIF and LED FM techniques using p 
value (< 0.05) level of significant. 
   
To evaluate the sensitivity and 
specificity of smear auramine FM to 
TB diagnosis in the study area. 
Pearson  chi-square test used to determine 
the different of two sides of Gene Xpert 
and LED FM techniques to generate 
positive and negative results of TB using p 
value (< 0.05) level of significant.   
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To determine the prevalence of 
MDR-TB in the study area 
Pearson chi-square test used to calculate 
the prevalence value of MDR-TB for those 
TB positive 
 
3.12 Limitation 
The limitation of this study was 10 patients failed to collect morning sample (second 
sample), so in this case were removed from the study because they did not adhered to 
the inclusion criteria. Also some of the clients refused to provide their telephone 
number because they thought of stigmatization. 
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CHAPTER FOUR 
RESULTS 
 
4.1 Characteristics of Study Participants 
The age of study participants ranged between 18 – 80 years and majority of them 
were females 136 (55.3%) as shown in Table 4.1. A high proportional of the patients 
were between ages of 31 to 40 years which account 66(26.8%). Majority of study 
participants lived in Urban district of Unguja (40.7%) which is located in Urban 
West region while high number of patients were living (80.9%) as shown in Figure 
4.1 and Figure 4.2. 
Table 4.1: Patients Age Groups and Sex 
Age 
group  
(years) 
 
Patient gender                     GeneXpert MTB/RIF technique results 
Male N(%) Female 
N(%) 
Total 
patients 
Total patients 
tuberculosis 
positive N(%) 
Positive 
tuberculosis 
Male N(%) 
Positive 
tuberculosis 
Female N(%) 
< 20 9(3.7%) 14(5.7%) 23(9.3%) 11(6.5%) 2(1.2%) 9(5.3%) 
21 - 30 25(10.2%) 33(13.4%) 58(23.6%) 44(26.0%) 23(13.6%) 21(12.4%) 
31 - 40 27(11.0%) 39(15.9%) 66(26.8%) 44(26.0%) 20(11.8%) 24(14.2%) 
41 - 50 26(10.6%) 32(13.0%) 58(23.6%)    41(24.3%)  21(12.4%) 20(11.8%) 
51 - 60 16(6.5%) 11(4.5%) 27(11.0%) 18(10.7%) 12(7.1%) 6(3.6%) 
> 61 7(2.8%) 7(2.8%) 14(5.7%) 11(6.5%) 7(4.1%) 4(2.4%) 
Total 110(44.7%)  136(55.3%) 246(100%) 169(100%) 85(50.3%) 84(49.7%) 
 
Among the male and female patients, the least proportional were in the age group 
above 61 years as shown in Table 4.1. Among 246 confirmed seropositive 
HIV/AIDS patients examined, 169 were pulmonary tuberculosis positive for Gene 
Xpert MTB/RIF technique. Among the HIV/AIDS patients that were positive of 
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pulmonary tuberculosis 85 (50.3%) were males and 84 (49.7%) were females as 
shown in Table 4.1. 
 
 
 
Figure 4.1: Distribution of Patients in Districts of Unguja Island 
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Figure 4.2: Distribution of Patients in Regions of Unguja Island 
 
4.2 Evaluation of the Accuracy of Gene Xpert MTB/RIF and LED FM for 
Diagnosis of PTB 
Sputum samples from HIV patients attended CTC at MMH Zanzibar who were 
suspected to have PTB were collected between 5
th
 April to 10
th
 August, 2015. A total 
of 246 patient‟s sputum samples came from seven districts of Unguja Island and 
were analyzed for the presence of M.tuberculosis. Comparison between Gene Xpert 
MTB/RIF and LED FM techniques was done and found that of the 246 patients 
examined for spot samples (sample I), 169 (68.7%) were positive for Gene Xpert 
technique while 112 (45.5%) were smear positive (LED FM). Also for morning 
samples (sample II) 169 (68.7%) were positive for Gene Xpert technique while 118 
(48.0%) were smear positive (LED FM) Table 4.2. This different is statistically 
significant (p=0.000). 
 
Table 4.2: Evaluation between Gene Xpert and LED FM in Positivity Results 
Sample Total 
number 
Smear Positive 
LED FM 
Gene Xpert 
Positive 
Absolute 
Difference 
Number % Number % % 
Spot sputum  
(sample I) 
246 112 45.5 169 68.7 23.2 
Morning sputum 
(sample II) 
246 118 48.0 169 68.7 20.7 
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4.3 Sensitivity and Specificity of Smear Auramine FM for PTB Diagnosis in 
the Study Area 
All 246 sputum samples collected were processed by Gene Xpert, as well as smear 
auramine FM in order to evaluate sensitivity and specificity of LED FM. Among 169 
spot and morning samples which were positive in Gene Xpert  processed by smear 
auramine. The sensitivity of LED FM in spot and morning samples were 66.3% and 
69.8% respectively. Also the specificity for both samples was 100% as shown in 
Table 4.3. In Figure 4.3 and 4.4 indicate percentage of grades AFB positivity for 
both samples in smear examination. This difference is statistical significance of 
(p=0.02) 
 
Table 4.3: Smear Auramine LED FM Results 
Fluorescent microscope Spot samples (sample I) Morning sample (sample II) 
Sensitivity 66.3% 69.8% 
Specificity 100% 100% 
Number of true positive 112 (66.3%) 118 (69.8%) 
Number of false positive 0 (0%) 0 (0%) 
Number of true negative 77 (31.3%) 77 (31.3%) 
Number of false negative 57 (33.7%) 51 (30.2%) 
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Figure 4.3: Distribution of Smear Positivity of Spot Sputum Samples 
   
Figure 4.4: Distribution of Smear Positivity of Morning Sputum Samples 
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4.4 Occurrence of MDR-TB in the Study Area 
Among 169 samples which were positive PTB cases two patients were found to have  
MDR-TB for rifampicin resistance in spot and morning samples of the same patients, 
so this account rifampicin resistance to about 1.2% of the positivity patients found in 
the study area. Therefore this indicates the prevalence of MDR-TB is 1.2%. Table 
4.4 shown the result generated by Gene Xpert Machine. 
 
Table 4.4: Gene Xpert Results for MTB/RIF Detection 
Gene Xpert result Frequency Percent 
MTB DETECTED 167 67.9 
MTB NOT DETECTED 77 31.3 
MTB DETECTED /RIF RES 2 0.8 
Total 246 100 
CHAPTER FIVE 
DISCUSSION 
 
5.1 Characteristics of Study Participants 
TB and HIV/AIDS can interact and exacerbates the disease situation. TB is the most 
common opportunistic disease and cause of the death for those infected with HIV 
(Friedland, 2007). Similarly, HIV infection is one of the most important risk factors 
associated with an increased risk of latent TB infection progressing to active TB 
disease (Girardi, 2000; Meya and Mc Adam, 2007). So the WHO‟s policy on 
collaborative TB/HIV activities recommends a combination of measure to reduce the 
burden of TB among HIV infected individuals (WHO, 2012). These measures 
include intensified case finding, isoniazid preventive therapy, and infection control 
and antiretroviral therapy. 
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Among the 169 HIV/AIDS patients having TB in this study, 85 (50.3%) were male 
and 84 (49.7%) were female and these agree with previous reports indicating higher 
prevalence in male than females (Homes, 1988;  Abeld, 2002). In our study, the age 
distribution reveals the majority of TB/HIV patients were 31 to 40 years old (26.8%), 
followed by 21 to 30 years old (23.6%), which represent the most sexually active age 
group and correlates with the study done by (Gyar, 2014). 
 
5.2 Evaluation of the Accuracy of Gene Xpert MTB/RIF and LED FM for 
Diagnosis of PTB 
In low income countries, TB diagnosis and treatment initiation is based on smear 
microscopy results. In our study, Gene Xpert MTB/RIF out performed smear 
microscopy for MTB detection in almost one third of the patients. The present study 
has several important finding: first controlled comprehensive clinical validation 
study of the diagnostic accuracy of LED FM in a patient suspected of having active 
PTB from HIV patient. Second, the study shows that LED FM has a low sensitivity 
and high specificity. Thirdly, the study shows that Gene Xpert MTB/RIF is more 
accuracy than LED FM. Fourthly, Gene Xpert assay was positive in 57 spot and 51 
morning samples which were smear negative in LED FM and were classified as 
having PTB. Lastly, the Gene Xpert MTB/RIF was easy to perform, gave results 
within two hours of sample processing and there were no operational difficulties 
during its usage. 
 
In the comparison between Gene Xpert MTB/RIF and smear auramine LED FM 
results, it was noted that Gene Xpert MTB/RIF increase the number of TB positive 
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results by 23.2% compared to smear auramine LED FM. The finding of this study 
does not concur with the study of (Alvares-Uria, 2012) who reported Gene Xpert 
MTB/RIF increase the number of positivity by 10.8% compared to LED FM in India. 
Also our finding does not concur with the study performed in South Africa with HIV 
infected patients that reported that Gene Xpert MTB/RIF increase case detection for 
TB by 45% compared to LED FM (Lawn, 2011). 
 
The different between three studies may be explained by the difference in 
populations of the studies and in the way the sputum specimens were collected. In 
the South African study, two sputum samples were collected in a single visit to out 
patient clinics before the initiation of antiretroviral treatment and regardless of 
symptoms (Lawn, 2011). In the Indian study, they studied patient with high 
suspicious of active tuberculosis infection, and all patients were admitted to the 
Hospital (Alvares-Uria, 2012).  
 
In this study, I examined patients with signs and symptoms of tuberculosis infection, 
and two sputum specimens were collected in a two visit to the CTC and TB clinics.In 
the present study no patient was found to have a false positive result in smear 
auramine LED FM. The 77 samples which were negative in Gene Xpert MTB/RIF 
were also processed in smear auramine LED FM, and also revealed negative results.  
 
One important limitation of the Gene Xpert MTB/RIF assay is that it can process a 
maximum of four samples every two hours, so it may not be suitable for a busy 
laboratories receiving large number of sample in resource limited setting (Alvares-
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Uria, 2012). The prompt results provided by Gene Xpert MTB/RIF would allow a 
timely diagnosis and prompt initiation of TB treatment. As extensively reported in 
the medical literature, the benefit of rapid treatment initiation of TB in HIV co-
infected patients could improve individual prognosis and reduce overall TB disease 
transmission (Sterling, 2010). 
 
My data suggest that smear negative TB patients could benefit from the new assay of 
Gene Xpert MTB/RIF assay in those areas where no culture is available. The Gene 
Xpert MTB/RIF assay could lead to avoid loss of patients and treatment delay in 
those TB suspect with a negative smear result. This could lead to the reduction of 
infection and improvements in TB control in the society.   
 
5.3 Sensitivity and Specificity of Smear Auramine LED FM for PTB 
Diagnosis in the Study Area  
The AFB staining method is the most common and supportive method in diagnosis 
of TB infection in resource limited settings. Although AFB staining method is a 
much cheaper, simple, and rapid method but also possess a low specificity and 
variable sensitivity (Reid, 2009). Current recommendation for the control of 
tuberculosis emphasizes early case detection so as to follow treatment of patients and 
there by limit the transmission of the bacilli. The main stay for its control is the rapid 
and accurate identification of the infected individuals (Prasanthi, 2005). 
 
In this study smear LED FM have shown higher specificity of 100% so this is similar 
to another study carried out in South Africa which showed specificity above 95 % by 
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(Lawn, 2011). Also in the present study sensitivity of smear LED FM was 69.8%, 
this does not agree with a study conducted in Uganda by (Yoon, 2012) that showed 
42% sensitivity. 
 
Tuberculosis control, especially in TB/HIV endemic areas with poor resources, is 
hampered by lack of sensitivity and specificity of sputum smear microscopy which is 
often the only diagnosis method in place. In December 2010, WHO endorsed the 
Gene Xpert MTB/RIF for wide spread use. Among other indications the assay has a 
strong recommendation as initial diagnostic test in individual with suspected HIV 
associated TB (WHO, 2010). HIV infected patients are to have smear negative 
sputum samples. This could be confirmed by our data that showed that 33.7% of spot 
samples and 30.2% of morning samples of negative smears were positive when 
processed by Gene Xpert MTB/RIF. In the present study indicated that smear LED 
FM has a lower sensitivity compared to the Gene Xpert MTB/RIF assay in diagnosis 
of HIV patients affected by PTB. 
 
Co-infection with TB/HIV leads to many challenges in both the diagnosis and 
treatment of TB. With increase in rates of drug resistance tuberculosis, including 
multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant 
tuberculosis (XDR-TB) mortality has increased. Sputum smear microscopy in HIV 
infected patients are not highly sensitive therefore newer diagnostic test are urgently 
required that are cheaper, sensitive, specific and easy to perform and use in remote 
and resource constrained settings (Solomon, 2013). Treatment is very important in 
prevention of TB and/or HIV which can only be done with a very effective 
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diagnostic tool. Thus an effective diagnostic tool is very crucial in diagnosing TB in 
early stage and in HIV patients to reduce mortality and spread of infection. 
 
5.4 Occurrence of MDR-TB in the Study Area 
Available data on the prevalence of XDR-TB and MDR-TB in Tanzania are still low 
owing to improved case management. Although the levels of anti-tuberculosis drug 
resistance in the country are still low, the need for continuous monitoring has always 
been emphasized (Chonde, 2010, and Range, 2012). The most effective strategies for 
limiting further spread of drug resistance tuberculosis include rapid detection of drug 
resistance followed by prompt and effective therapy of each case. Routine 
surveillance linked to patient care, represents the best approach to monitor drug 
resistance (Hoza, 2015). 
The present study has demonstrated a significant increase of positive results when 
comparing Gene Xpert MTB/RIF with LED FM when performing both tests in the 
same sputum sample. In this study two (1.2%) out of 169 samples with valid 
rifampicin resistant were found. This indicates that the prevalence of MDR-TB is 
1.2% in Zanzibar. This results do not concur with the study of (Alvares-Uria, 2012) 
who reported six (4.8%) out of 124 specimens in India. Also the results do not 
concur with the study of (Hoza, 2015) conducted in Tanga, Tanzania Mainland that  
showed the prevalence of MDR-TB to rifampicin resistant was 6.3%. The reasons for 
the difference between the prevalence in Tanzania Mainland and Zanzibar could be 
that in Tanzania Mainland more study have been conducted to find the prevalence of 
MDR-TB compared to Zanzibar. Also population difference between Zanzibar and 
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Tanzania Mainland could lead to higher prevalence of MDR-TB in Mainland than 
Zanzibar. 
 
 
 
 
 
 
 
 
CHAPTER SIX 
CONCLUSIONS AND RECOMMENDATIONS 
 
6.1 Conclusions 
The results of this study indicated that Gene Xpert MTB/RIF is more accuracy than 
LED FM in diagnosis of PTB in HIV patients suspected with TB. It is usefulness to 
detecting sputum smear negative patients needs further examination. The sensitivity 
of LED FM in diagnosis of PTB in HIV patient suspected with TB is lower and their 
specificity is higher. In our study, active case finding using the Gene Xpert 
MTB/RIF analysis has increased active PTB case detection among HIV infected 
patients. 
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The study has showed that spot and morning sputum samples of the same patients 
yielded the same results when examined in Gene Xpert MTB/RIF, therefore Gene 
Xpert MTB/RIF may be useful as a sole rapid test for PTB case detection in HIV 
patients suspected with TB, particularly in settings lacking capacity for liquid 
culture. Lastly the prevalence of MDR-TB rifampicin resistance is lower in Zanzibar 
it might be in the cause of increasing. 
 
6.2 Recommendation  
A single spot or single morning sputum sample is enough to examine PTB from HIV 
infected patients by using Gene Xpert MTB/RIF. This will lead to release the 
patients‟ results on the same day of the sample collection and will eliminate patients 
drop out as well as decrease costing of the patients to return at a health facility to 
submit the second sputum sample and to get the results at the following day. Policy 
makers should procure and disseminate the Gene Xpert MTB/RIF machine at least to 
the district Hospitals so that to increase case detection of PTB from the HIV infected 
patients in order to provide early treatment to patients who have active PTB cases 
and to protect environmental pollution.  
 
 Also the study recommends expansion of MDR-TB surveillance to cover all patients 
with history of previous treatment for TB, all patients with infectious TB (sputum 
smear positive TB patients), contacts of known MDR-TB cases and all HIV positive 
TB patients. HIV positive patients should be screen for TB. Lastly the use of faster 
MDR-TB diagnostic methods such as Gene Xpert MTB/RIF to detect drug resistance 
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within two hours should be considered for screening among HIV positive TB and 
among sputum smear positive TB cases that are likely to transmit MDR-TB. 
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APPENDICES 
 
Appendix  1: Consent Form 
 
STUDY TITLE: ASSESSMENT OF TWO TECHNIQUES FOR DIAGNOSIS 
PULMONARY TUBERCULOSIS IN HIV PATIENT AT MNAZI MMOJA 
HOSPITAL ZANZIBAR: GENE XPERT AND FLUORESCENT 
MICROSCOPY 
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You are being asked for your consent to participate in a study that involves 
tuberculosis suspect in HIV patients in this hospital. We are asking for your consent 
to participate in a medical research study .The study is done by Abdalla Said 
Mohamed , the Master‟s student of environment Health at Open University of 
Tanzania. I will explain the study to you and will ask if you are willing to participate. 
 Take your time to make your decision about participating.  You may discuss your 
decision with your family and friends and with your health care team.  If you have 
any questions, you may ask the researcher. 
 
Purpose of the study 
To compare Gene Xpert MTB/RIF and LED fluorescent microscopy for diagnosis of 
pulmonary TB in HIV patients. This study is not funded by any institution. None of 
the researchers have potential financial gain from the study. 
 
Study procedure 
If you take part in this research study, we will ask you to give us the specimen of 
sputum. This is an activity that is part of the services provided by the tuberculosis 
clinic. 
Procedure for specimen donation 
If you agree to participate in this study, the following will happen: 
 Your sputum will be tested and its result will be coded to safeguard their 
privacy per protocol. 
 There will be no direct benefit to you 
 There will be no human genetic tests performed to your samples. 
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Withdraw from the study 
 You can decide to withdraw from the study at any time.  You will tell the 
researcher if you are thinking about stopping or decide to stop. Notify the 
researcher at MMH (Abdalla S. Mohamed) in writing at Mnazi Mmoja Hospital, 
P.O.Box 236, Zanzibar, Tanzania or by Mobile: +255 (0)777 435441, and he will 
destroy any your identifiable.  He will tell you how to stop your participation 
safely.  
Risk and Benefits for participating in this study 
Testing the specimens will not cause any risk to you. 
There will be no direct benefit to you from participating in this study. You may 
choose not to participate. You will receive the same care whether you participate in 
the study or not. 
Private and confidentiality 
We will do our best to make sure that the results kept private.  
Costs 
You will not be charged for any of the study activities. 
Payments for your participation 
You will not be paid for taking part in this study. 
 
Participant’s right 
Taking part in this study is your choice.  You may choose either to take part or not to 
take part in the study.  If you decide to take part in this study, you may leave the 
study at any time.  No matter what decision you make, there will be no penalty to 
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you and you will not lose any of your regular benefits.  Leaving the study will not 
affect your medical care.  You can still get your medical care from the health 
facilities in Zanzibar as well as the whole Tanzania.  
 
Consent 
You have been given copies of this consent form. 
 
Participation in research is voluntary 
You have the right to decline to participate or to withdraw at any point in this study 
without penalty or loss of benefits to which you are otherwise entitled. 
If you wish to participate in this study, you should sign below. 
________________ ________________ ___________________________  
Date   Participant's  name Participant's Signature for Consent 
 
________________  ________________  ___________________ 
Date    Person Obtaining Consent                  Signature 
 
Appendix  2: SOP for Auramine Staining Fluorescent Microscopy  
 
1. Scope 
This procedure applies to all laboratory personnel who perform auramine staining to 
diagnose microscopically tuberculosis. 
2. Principle               
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Sputum smears are stained with auramine which stains Mycobacterium tuberculosis 
in greenish yellow against a dark background. 
3. Specimen type 
Sputum           
4. Material and equipment       
- Timer 
- Fluorescent microscope 
- Bunsen burner or alcohol lamp 
-  Slide rack to support slides over the sink 
- Slide rack for drying stained slides 
- Sink with water 
- Forceps 
- Diamond pencil 
- Waste bin 
- Positive and negative control slides  
- Paper filters 32.0 cm in size 
- Gloves 
-  0.1% of auramine 
- 0.5% of acid-alcohol 
- 0.5 of patassium permanganate or 0.3 of methylene blue 
5. Safety precaution 
- Specimen may contain live potentially infectious agents that hazardous to your 
health Observe Standard Universal Precautions. 
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- Ensure that the work surface is kept clean, free from clutter and other infectious 
substances to avoid contamination. 
- Spills should be immediately disinfected with appropriate disinfectant solution. 
6. Quality control 
- Positive and negative control slides must be used  
- Ensure that reagents are not expired 
7. Calibration 
Ensure that the fluorescent microscope is regularly maintained 
8. Activity description 
- Wear appropriate PPE 
- Gather necessary materials and reagents  
-  Filter auramine solution prior to use 
- Put the slides on the staining rack, smear facing upward 
- Cover all the slides with the filtered auramine 
- Leave the stain on slides for minimum of 20 minutes 
- Gently rinse each slide with water 
- Till each slide off excess water 
- Cover the slides with acid-alcohol and leave on for 1-2 minutes 
- Gently rinse each slide with water and do not splash other slides 
- Till each slide off excess water 
- Cover each slide with potassium permanganate or methylene blue for 1 minute 
- Gently rinse each slide with water and do not splash other slides 
- Till each slide off excess water 
- Air dry away from direct sunlight. Do not examine slides until they have dried 
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9. Calculation 
NA 
10. Reading smears and reporting of results                     
- Place the slide on the microscope and ensure that the smear is facing upward 
- Use 20-25X objective to scan the smear and 40X objective for confirming 
suspicious objects  
1.1.1  
N of AFB Report 
No AFB/1 length Negative 
1-29 AFB/1 length Record exact number 
1 - 9 AFB/ fields on average 1+ 
10-100 AFB/ field on average 2+ 
> 100 AFB/ field on average 3+ 
 
 Reference range 
NA                                                                          
 References                     
- Jane Carter &Orgenes Lema: Practical laboratory manual for health centers in 
Eastern Africa. 
- Laboratory Diagnosis of tuberculosis by Sputum Microscopy. The Handbook 
Tanzania 2009. 
Appendix  3: SOP for Sample Processing for Diagnosis and Rifampicin 
Resistance in Gene Xpert MTB/ Rif 
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1.0.Title  
Standard Operating Procedures for TB diagnosis and Rif resistance using the Xpert 
MTB/Rif on sputum 
 
2.0 Objective and Scope 
This SOP describes how to use the Gene Xpert instrument and how to perform the 
Xpert MTB/Rif assay. To ensure that all trained health care providers are capable of 
performing the Xpert MTB/RIF assay for diagnosing TB in sputum specimens 
directly in a primary health care facility, according to the manufacturer‟s 
instructions. Standard operating procedure for sample processing for Gene Xpert 
used in detection of mycobacterium and Rifampicin testing. 
 
2.1 Principle 
The GeneXpert (Cepheid) is a closed, self-contained platform for the extraction, 
amplification and detection of Mycobacterium tuberculosis (Mtb) complex from 
unprocessed samples. The GeneXpert system is able to generate a result within 2 
hours. 
 
The Xpert MTB/RIF assay allows for the rapid detection of Mtb and Rifampicin 
(Rif) resistance by combining automated extraction, amplification and detection on a 
single system. Rif is one of the first line anti-TB drugs and is also a surrogate marker 
for multi-drug resistant TB (MDR-TB). The assay amplifies a portion of the 
“rifampicin resistance determining region” of the rpoB gene, the most common site 
for Rif mutations, in real-time, using two sets of primers. Fluorescent probes are then 
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used to differentiate between wild-type and mutant strains so that if one or more 
probes do not bind, this indicates the presence of a mutation and therefore Rif 
resistance. 
 
A sample processing control (SPC) consisting of spores from Bacillus globigii, is 
included in the assay as an internal control to ensure adequate processing of the 
sample as well as to monitor the presence of PCR inhibitors. A probe check control 
(PCC) verifies reagent rehydration, PCR tube filling in the cartridge, probe integrity 
and dye stability. 
 
3.0 Safety and environment 
Refer to Health Laboratory Safety and Waste Management Manual for safety 
considerations 
• The GeneXpert system should be installed on a solid, even base 
• Always wear a lab coat and disposable gloves  
• All sample processing should take place under a BioSafety Cabinet Class II hood 
OR an open, well-ventilated area. 
• Treat all samples as potentially infectious 
• If liquid containing potentially infectious agent is spilled, clean affected area with 
3.5% hypochloride 
• Dispose of all waste in a biohazard medical waste bin 
4.0 Procedure 
Materials 
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Reagents Supplies Equipment 
 GeneXpert Kit including: 
Xpert cartridges, sterile 
disposable transfer 
pipettes, Sample Reagent 
(SR) buffer (Pro-Gen 
Diagnostics) 
 Tap Water 
 70% Ethanol 
 3.5% or 5% Sodium 
hypochlorite (Bleach) 
 Screw-capped 
sputum containers 
 Pasture pipette  
 Disposable Gloves 
 Laboratory coat 
 Soap 
 Permanent 
marking pens 
 Tidy wipe/paper towel 
 Biohazard medical 
waste bin 
 The GeneXpert Dx 
System includes 
GeneXpert instrument, 
computer and barcode 
scanner, UPS, printer 
(Pro-Gen Diagnostics) 
 Stop watch/timer 
 500ml measuring 
cylinder 
 Memory stick/RW-
CD‟s for data backup 
 
NOTE: Always wear gloves and laboratory coat when processing sputum specimens 
and Sample preparation should take place in a Biosafety Cabinet Class II if available 
OR a designated open, well ventilated work area in the laboratory! 
5.0 Collection of sputum specimen 
 Explain the specimen collection procedure to the patient 
 Provide patient with the screw-capped container. 
 Instruct patient to cough deeply and spit up sputum into the screw-capped 
sputum container. 
 Instruct patient to seal the specimen container tightly. 
 Ensure the sputum in the container is sent to the laboratory. 
 Label each specimen immediately with identifying information – patient    name, 
date and time of collection 
 Log the sputum specimen in  laboratory log book/computer system 
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 6.0       Sample preparation  
1. For each of the sample: unscrew the lid of sputum collection container 
2. Add directly in the collection container 2 volumes of the sample reagents to 1 
volume of sample. 
3. Replace the lid, and shake vigorously 10 – 20 times.(Note: one back and forth 
movement is a single shake) 
4. Incubate at room temperature: After 10 minutes of incubation, shake ( or vortex) 
the specimen vigorously 10 – 20 times. 
5. After 5 minutes of incubation. Sample should be perfectly fluid before being 
processed, with no visible clumps of sputum. If still viscous, wait 5 – 10 further 
minutes before processing it in the cartridge. 
NOTE: The unprocessed sputum specimen can be stored at 4⁰C for 4-10days 
7.0 Cartridge preparation 
1. Label the cartridge with the sample ID by writing on the left or right side of the 
cartridge or affix ID label. 
2. Open the cartridge ,pipette at least 2 ml with the plastic transfer pipette from the 
collection container to the cartridge, then close the cartridge lid. 
Note: Do not put the label on the lid of the cartridge or obstruct the existing 2d 
barcode on the cartridge, 
8.0 References 
 Operators Manual for the GeneXpert system (Cepheid). 
Or contact: Pro-Gen Diagnostics on 011 467 751 
 
